Enzymatica publ AB

Research Enzymatica publ AB (ENZY) on Bullrun: market cap SEK 461.20M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is SEK 461.20M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025SEK 53.91M-SEK 51.93Mn/a61.4%n/aSEK 33.13MSEK 1.02MSEK 124.17M
FY2024SEK 45.58M-SEK 52.67Mn/a67.4%n/aSEK 75.21MSEK 2.20MSEK 176.37M
FY2023SEK 50.90M-SEK 48.95Mn/a62.6%n/aSEK 8.37Mn/an/a
FY2022SEK 48.95M-SEK 68.55Mn/a58.1%n/aSEK 50.69Mn/an/a

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25SEK 461.20Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 SEK.

About Enzymatica publ AB

Enzymatica AB (publ), a life science company, develops and sells medical devices for infectious diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care under Penzyme technology. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Enzymatica publ AB's market cap?

Enzymatica publ AB's market capitalization is SEK 461.20M.

What does Enzymatica publ AB do?

Enzymatica AB (publ), a life science company, develops and sells medical devices for infectious diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care under Penzyme technology. The company was incorporated in 2007 and is headquartered in Lund, Sweden.